damaldumil/obesity

Adipocyte-Derived Serum Amyloid A3 and Hyaluronan Play a...

Rated Nov 06 2007 • 0 reviews • diabetes, obesity, adipocyte • diabetesjournals.org

• Share

Obesity Online Slides: triglyceride levels, type 2...

Rated Oct 28 2007 • 0 reviews • diabetes, obesity, insulin, online ppts • obesityonline.org

• Share

Hypothalamic regulation of pancreatic secretion is...[J...

Rated Oct 25 2007 • 0 reviews • genetics, obesity, histamine signaling • nih.gov

• Share

Insulin-Sensitive Protein Kinases (Atypical Protein...

Rated Oct 07 2007 • 1 review • diabetes, review, obesity • ebmonline.org

At this point, we are working under the conviction that our opinions on aPKC and PKB are correct, and we optimistically believe that we are at, or close to, an understanding of why insulin fails to work effectively in stimulating glucose uptake in muscle and, on the other hand, is overactive in stimulating lipid synthesis in the liver in insulin-resistant hyperinsulinemic states. Accordingly, we believe that we are on the threshold for devising better programs for treating the "metabolic" or "insulin resistance" syndrome seen in obesity and Type II diabetes mellitus.

• Share

Obesity is associated with macrophage accumulation in...

Rated Oct 04 2007 • 1 review • obesity, macrophage • nih.gov

From the page: "Obesity alters adipose tissue metabolic and endocrine function and leads to an increased release of fatty acids, hormones, and proinflammatory molecules that contribute to obesity associated complications. To further characterize the changes that occur in adipose tissue with increasing adiposity, we profiled transcript expression in perigonadal adipose tissue from groups of mice in which adiposity varied due to sex, diet, and the obesity-related mutations agouti (Ay) and obese (Lepob). We found that the expression of 1,304 transcripts correlated significantly with body mass. Of the 100 most significantly correlated genes, 30% encoded proteins that are characteristic of macrophages and are positively correlated with body mass. Immunohistochemical analysis of perigonadal, perirenal, mesenteric, and subcutaneous adipose tissue revealed that the percentage of cells expressing the macrophage marker F4/80 (F4/80+) was significantly and positively correlated with both adipocyte size and body mass. Similar relationships were found in human subcutaneous adipose tissue stained for the macrophage antigen CD68. Bone marrow transplant studies and quantitation of macrophage number in adipose tissue from macrophage-deficient (Csf1op/op) mice suggest that these F4/80+ cells are CSF-1 dependent, bone marrowâ€"derived adipose tissue macrophages. Expression analysis of macrophage and nonmacrophage cell populations isolated from adipose tissue demonstrates that adipose tissue macrophages are responsible for almost all adipose tissue TNF-α expression and significant amounts of iNOS and IL-6 expression. Adipose tissue macrophage numbers increase in obesity and participate in inflammatory pathways that are activated in adipose tissues of obese individuals."

• Share

1206_article_01

Rated Sep 23 2007 • 1 review • weight loss, obesity, adipokines, adipose • krakow.pl

ADIPOCYTOKINES - NOVEL LINK BETWEEN INFLAMMATION
AND VASCULAR FUNCTION?

• Share

PRESS RELEASE: NeuroSearch announces PhaseIIb obesity...

Rated Sep 18 2007 • 0 reviews • drugs, obesity • fiercebiotech.com

• Share

PRESS RELEASE: Vernalis Announces Striking Weight Loss in...

Rated Sep 18 2007 • 1 review • drugs, obesity • fiercebiotech.com

LONDON, Sept. 13, 2007-Vernalis today announced the results of its Phase I programme with the CB1 antagonist, V24343 which has completed two Phase I studies: a single and multiple ascending dose study for up to 14 days, and a food effect study.

* Striking weight loss over 16 days in overweight and mildly obese volunteers
* Evaluated in a total of 66 volunteers
* Generally well tolerated with no serious adverse events
* Evidence of efficacy also demonstrated by clinically relevant reductions in body fat, energy intake and waist circumference
* Pre-clinical data demonstrated significant safety differences from Sanofi-aventis CB1 antagonist, rimonabant.

• Share